Trials / Withdrawn
WithdrawnNCT00768612
Study Evaluating Safety and Tolerability of Vabicaserin in Patients With Sudden Worsening of Schizophrenia
A Randomized, Double-Blind, Risperidone-Reference, Parallel-Group, Safety, and Tolerability Study of Vabicaserin (SCA-136) in Japanese Subjects With Acute Exacerbation of Schizophrenia
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 20 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the clinical safety and tolerability of vabicaserin in Japanese subjects that have a sudden worsening of their symptoms of schizophrenia. The study will also assess the efficacy of vabicaserin and compare it to risperidone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SCA-136 50mg/day | |
| DRUG | SCA-136 150 mg/day | |
| DRUG | SCA-136 300mg/day | |
| DRUG | Risperidone 4mg/day |
Timeline
- Start date
- 2008-11-01
- Primary completion
- 2009-07-01
- Completion
- 2009-07-01
- First posted
- 2008-10-08
- Last updated
- 2013-01-29
Source: ClinicalTrials.gov record NCT00768612. Inclusion in this directory is not an endorsement.